Purpose: The proinflammatory cytokine tumor necrosis factor-alpha has an important role in the pathogenesis of prostate cancer. Single nucleotide polymorphisms in the promoter region of the TNF-A gene alter tumor necrosis factor-alpha transcription. Thus, we studied the association of 4 SNPs in the promoter region of TNF-A gene, including -1031T>C, -863C>A, -857 C>T and -308 G>A, in a North Indian cohort of patients with prostate cancer.

Materials And Methods: The study involved 453 subjects. All 197 case and 256 control samples were genotyped for the 4 promoter polymorphisms in the TNF-A gene using allele specific polymerase chain reaction and polymerase chain reaction-restriction fragment length polymorphism.

Results: Results showed an increased risk of prostate cancer for the TNF-A -1031 CC genotype (OR 2.01, p = 0.03). No significant association was observed for the TNF-A -863 C>A, TNF-A -857 C>T or -308 G>A polymorphisms. Haplotype analysis revealed that TNF-A -1031C-863C-857T-308G was significantly associated with prostate cancer risk (OR 2.22, p = 0.013). Moreover, the TNF-A -1031 C and -857 T alleles were associated with higher tumor grade and an increased risk of tumor progression and metastasis.

Conclusions: These results show that TNF-A polymorphisms have an important role in prostate cancer pathogenesis. Results are in line with findings in other studies from the West and to our knowledge for the first time from India indicating the involvement of immune system genes in prostate cancer pathogenesis.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2009.08.016DOI Listing

Publication Analysis

Top Keywords

prostate cancer
24
tumor necrosis
12
tnf-a gene
12
tnf-a
9
cancer risk
8
north indian
8
indian cohort
8
necrosis factor-alpha
8
promoter region
8
region tnf-a
8

Similar Publications

Objective: To assess the association between prostate-specific antigen (PSA) density (PSAD) and prostate cancer mortality after a benign result on systematic transrectal ultrasonography (TRUS)-guided prostate biopsy.

Patients And Methods: This retrospective study used data from the Finnish Randomised Study of Screening for Prostate Cancer (FinRSPC) collected between 1996 and 2020. We identified men aged 55-71 years randomised to the screening arm with PSA ≥4.

View Article and Find Full Text PDF

Patient stratification remains a challenge for optimal treatment of prostate cancer (PCa). This clinical heterogeneity implies intra-tumoural heterogeneity, with different prostate epithelial cell subtypes not all targeted by current treatments. We reported that such cell subtypes are traceable in liquid biopsies through representative transcripts.

View Article and Find Full Text PDF

Background The accurate diagnosis of intraductal carcinoma of the prostate (IDC-P) is occasionally challenging due to the similarity in pathological morphology between IDC-P and high-grade prostatic intraepithelial neoplasia (HGPIN). In this report, we reviewed the pathology of cases previously diagnosed as HGPIN to search for IDC-P cases effectively. In addition, we examined whether those cases had genetic abnormalities.

View Article and Find Full Text PDF

Obesity, dietary interventions and microbiome alterations in the development and progression of prostate cancer.

Front Immunol

January 2025

Division of Pharmacology and Toxicology, College of Pharmacy, The University of Texas at Austin and Center for Molecular Carcinogenesis and Toxicology, The University of Texas at Austin, Austin, TX, United States.

Purpose Of Review: The role of the microbiome in prostate cancer is an emerging subject of research interest. Certain lifestyle factors, such as obesity and diet, can also impact the microbiome, which has been implicated in many diseases, such as heart disease and diabetes. However, this link has yet to be explored in detail in the context of prostate cancer.

View Article and Find Full Text PDF

Purpose: To develop novel nomograms for predicting prostate cancer (PCa) and clinically significant prostate cancer (csPCa) in patients with prostate-specific antigen (PSA) < 10 ng/ml and PI-RADS v2.1 score ≤ 3.

Methods: We retrospectively collected data from 327 men with PSA < 10 ng/ml and PI-RADS score ≤ 3 from June 2020 to June 2024 in our hospital.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!